Filtros de búsqueda

Lista de obras de Jaap Verweij

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

artículo científico publicado en 2010

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

artículo científico publicado en 2015

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan

artículo científico publicado en 2010

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients

artículo científico publicado en 2012

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform

artículo científico publicado en 2013

A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer

artículo científico publicado en 2004

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

scientific article published on 29 September 2004

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

artículo científico publicado en 2012

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

artículo científico publicado en 2004

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

artículo científico publicado en 2006

A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens

artículo científico publicado en 2008

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

artículo científico publicado en 2012

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

artículo científico publicado en 2004

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

artículo científico publicado en 2009

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

artículo científico publicado en 2012

Alternative drug formulations of docetaxel: a review

artículo científico publicado en 2007

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients

artículo científico publicado en 2008

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

artículo científico publicado en 2006

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel

scientific article published on 01 November 2005

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

artículo científico publicado en 2006

Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction

artículo científico publicado en 2011

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 5 de octubre de 2011

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

artículo científico publicado en 2006

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

artículo científico publicado en 2013

Cancer clinical trial outcomes: any progress in tumour-size assessment?

artículo científico publicado en 2008

Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.

artículo científico publicado en 2009

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

artículo científico publicado en 2010

Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer

artículo científico publicado en 2009

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

artículo científico publicado en 2005

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia

artículo científico publicado en 2007

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

artículo científico publicado en 2009

Clinical pharmacokinetics of docetaxel : recent developments

artículo científico publicado en 2006

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

artículo científico publicado en 2002

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

artículo científico publicado en 2002

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins

artículo científico publicado en 2003

Clinical studies of camptothecin and derivatives

artículo científico publicado el 1 de enero de 2003

Clinical trial design for target specific anticancer agents

artículo científico publicado en 2003

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

artículo científico publicado en 2002

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

artículo científico publicado en 2004

Complementary and alternative medicine during cancer treatment: beyond innocence

artículo científico publicado en 2006

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

artículo científico publicado en 2012

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.

artículo científico publicado en 2010

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis

artículo científico publicado en 2008

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

artículo científico publicado en 2014

Determination of fraction unbound docetaxel using microequilibrium dialysis

artículo científico publicado en 2004

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection ⬇️

artículo científico publicado el 5 de octubre de 2003

Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection

artículo científico publicado en 2004

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry

artículo científico publicado en 2002

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography

artículo científico publicado en 2002

Determining the best dose for the individual patient

artículo científico publicado en 2011

Determining the optimal dose in the development of anticancer agents

artículo científico

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

artículo científico publicado en 2015

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

artículo científico publicado en 2011

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

artículo científico publicado en 2004

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

artículo científico publicado en 2003

Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches

artículo científico publicado en 2003

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate

artículo científico publicado en 2008

Distribution of paclitaxel in plasma and cerebrospinal fluid

artículo científico publicado en 2003

Docetaxel administration schedule: from fever to tears? A review of randomised studies

artículo científico publicado en 2005

Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

article

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

artículo científico publicado en 2014

Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment

artículo científico publicado en 2008

Drug transporters and imatinib treatment: implications for clinical practice

artículo científico publicado en 2010

Drug transporters of platinum-based anticancer agents and their clinical significance

artículo científico publicado en 2011

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

artículo científico publicado en 2010

Effect of ABCG2 genotype on the oral bioavailability of topotecan

artículo científico publicado en 2005

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

artículo científico publicado en 2018

Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.

artículo científico publicado en 2008

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

artículo científico publicado en 2005

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

artículo científico publicado en 2004

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor ⬇️

artículo científico publicado el 26 de junio de 2011

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

artículo científico publicado en 2011

Effect of valspodar on the pharmacokinetics of unbound paclitaxel ⬇️

artículo científico publicado el 1 de agosto de 2003

Effects of Mannose-Binding Lectin Polymorphisms on Irinotecan-Induced Febrile Neutropenia ⬇️

artículo científico publicado el 7 de octubre de 2010

Effects of St. John's wort on irinotecan metabolism

artículo científico publicado en 2002

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

artículo científico publicado en 2002

Effects of methimazole on the elimination of irinotecan.

artículo científico publicado en 2010

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

artículo científico publicado en 2006

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

artículo científico publicado en 2007

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values

artículo científico publicado en 2006

Evaluation of patient enrollment in oncology phase I clinical trials.

artículo científico publicado en 2013

Factors affecting cytochrome P-450 3A activity in cancer patients.

artículo científico publicado en 2004

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

artículo científico publicado en 2004

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

artículo científico publicado en 2007

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations

scientific article published on March 2010

GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design

artículo científico publicado en 2008

Gynaecological sarcomas

artículo científico publicado en 2007

Health policy: Affordability of drugs used in oncology health care

artículo científico publicado en 2016

Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

artículo científico publicado en 2006

Imatinib and gastrointestinal stromal tumors: Where do we go from here?

artículo científico publicado en 2005

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

artículo científico publicado en 2004

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

artículo científico publicado en 2002

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

artículo científico publicado en 2007

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study

artículo científico publicado en 2010

Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples

artículo científico publicado en 2004

Individual patient data analysis to assess modifications to the RECIST criteria.

artículo científico publicado en 2008

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel

artículo científico publicado en 2002

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

artículo científico publicado en 2004

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

artículo científico publicado en 2006

Influence of ketoconazole on the fecal and urinary disposition of docetaxel

artículo científico publicado en 2007

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy

artículo científico publicado en 2012

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

artículo científico publicado en 2005

Interaction of Cisplatin with the human organic cation transporter 2.

artículo científico publicado en 2008

Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity

artículo científico publicado en 2007

Irinotecan pathway genotype analysis to predict pharmacokinetics

scientific journal article

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature

artículo científico publicado en 2008

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

artículo científico publicado en 2006

Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib

artículo científico publicado en 2007

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development

artículo científico publicado en 2012

Lifestyle habits as a contributor to anti-cancer treatment failure

artículo científico publicado en 2008

Limited cerebrospinal fluid penetration of docetaxel

artículo científico publicado en 2004

Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices

artículo científico publicado en 2004

Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity

artículo científico publicado en 2003

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

artículo científico publicado en 2009

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

artículo científico publicado en 2009

Mechanism-based models for topotecan-induced neutropenia

artículo científico publicado en 2004

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

artículo científico publicado en 2005

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel

artículo científico publicado en 2007

Medicinal cannabis in oncology

artículo científico publicado en 2007

Medicinal cannabis in oncology practice: still a bridge too far?

artículo científico publicado en 2005

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

artículo científico publicado en 2014

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α

artículo científico publicado en 2014

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

artículo científico publicado en 2013

Modulation of irinotecan metabolism by ketoconazole

artículo científico publicado en 2002

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design ⬇️

artículo científico publicado el 16 de febrero de 2012

Multitarget tyrosine kinase inhibition: [and the winner is...].

scientific article published on 01 June 2007

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

artículo científico publicado en 2010

Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib

scientific article published on 01 June 2006

O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives

artículo científico publicado en 2002

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

artículo científico publicado en 2005

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

artículo científico publicado en 2012

Paclitaxel pharmacokinetics, threshold models, and dosing strategies.

artículo científico publicado en 2003

Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?

artículo científico publicado en 2005

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

artículo científico publicado en 2012

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

artículo científico publicado en 2009

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

artículo científico publicado en 2006

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

artículo científico publicado en 2004

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

artículo científico publicado en 2003

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan

artículo científico publicado en 2002

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

artículo científico publicado en 2005

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer

artículo científico publicado en 2003

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

artículo científico publicado en 2005

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

artículo científico publicado en 2012

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

artículo científico publicado en 2005

Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer

artículo científico publicado en 2004

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

artículo científico publicado en 2005

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity

artículo científico publicado en 2002

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

artículo científico publicado en 2002

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

artículo científico publicado en 2009

Phase I drug combination trial design: walking the tightrope

artículo científico publicado en 2009

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

artículo científico publicado en 2009

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

artículo científico publicado en 2005

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

artículo científico publicado en 2003

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer

artículo científico publicado en 2005

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

artículo científico publicado en 2009

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors ⬇️

artículo científico publicado el 12 de diciembre de 2011

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

artículo científico publicado en 2005

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

article

Population pharmacokinetics of cisplatin in adult cancer patients

artículo científico publicado en 2004

Practical aspects of managing gastrointestinal stromal tumors.

artículo científico publicado en 2006

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

artículo científico publicado en 2002

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria

article

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

artículo científico publicado en 2004

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

article by Stefan Sleijfer et al published January 2010 in European Journal of Cancer

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

artículo científico publicado en 2004

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

artículo científico publicado en 2006

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

artículo científico publicado en 2005

QTc prolongation and/or oncology drug development: who's in danger?

artículo científico publicado en 2008

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method

artículo científico publicado en 2006

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel

artículo científico publicado en 2003

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis

artículo científico publicado en 2003

Relationship of systemic exposure to unbound docetaxel and neutropenia.

artículo científico publicado en 2005

Renal toxicities of chemotherapy

artículo científico publicado en 2006

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

artículo científico publicado en 2002

Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors

artículo científico publicado en 2003

Role of pharmacogenetics in irinotecan therapy

artículo científico publicado en 2005

SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors

artículo científico publicado en 2012

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry

artículo científico publicado en 2004

Soft tissue sarcomas of adults: state of the translational science.

artículo científico publicado en 2003

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan

artículo científico publicado en 2002

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

artículo científico publicado en 2018

Targeted therapy: ready for prime time?

artículo científico publicado en 2004

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointesti

artículo científico publicado en 2017

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

artículo científico publicado en 2006

The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases.

artículo científico publicado en 2014

The epothilone dilemma

artículo científico publicado en 2005

The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients

artículo científico publicado en 2013

The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.

artículo científico publicado en 2012

The multi-institutional phase I study: disadvantages without advantages?

scientific article published on 01 April 2008

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

artículo científico publicado en 2007

The potential of statins as part of anti-cancer treatment

artículo científico publicado en 2005

The relevance of microdialysis for clinical on:cology

artículo científico publicado en 2006

Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study

artículo científico publicado en 2011

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

artículo científico publicado en 2014

Tumor volume as an alternative response measurement for imatinib treated GIST patients

artículo científico publicado en 2012

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

artículo científico publicado en 2002

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care

artículo científico publicado en 2005

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

artículo científico publicado en 2009

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda